Pérez Álvarez Sandra Ileana1, Ramos Prudencio Rubi1, Lozano Ruiz Francisco Javier2, Macías González Monserrat Del Sagrario3, Flores Balcazar Christian Haydeé1. 1. Radiotherapy and Medical Physics Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. 15 Vasco de Quiroga, Belisario Domínguez, Sección XVI, Tlalpan, Mexico City, 14080, Mexico. 2. Department of Radiation Oncology, Médica Sur Hospital. 150 Puente de Piedra, Toriello Guerra, Tlalpan, Mexico City, 14050, Mexico. 3. Hospital de Especialidades No. 25, Centro Médico del Noroeste. Lincoln y Fidel Velázquez Ave, Mitras Norte. Monterrey, Nuevo León, 64180, Mexico.
Abstract
AIM: Describe characteristics and outcomes of three patients treated with pelvic radiation therapy after kidney transplant. BACKGROUND: The incidence of pelvic cancers in kidney transplant (KT) recipients is rising. Currently it is the leading cause of death. Moreover, treatment is challenging because anatomical variants, comorbidities, and associated treatments, which raises the concern of using radiotherapy (RT). RT has been discouraged due to the increased risk of urethral/ureteral stricture and KT dysfunction. MATERIALS AND METHODS: We reviewed the electronic health records and digital planning system of patients treated with pelvic RT between December 2013 and December 2018 to identify patients with previous KT. CASES DESCRIPTION: We describe three successful cases of KT patients in which modern techniques allowed full standard RT for pelvic malignances (2 prostate and 1 vaginal cancer) with or without elective pelvic nodal RT, without allograft toxicity at short and long follow-up (up to 60 months). CONCLUSION: When needed, RT modern techniques remain a valid option with excellent oncologic results and acceptable toxicity. Physicians should give special considerations to accomplish all OAR dose constraints in the patient's specific setting. Recent publications recommend KT mean dose <4 Gy, but graft proximity to CTV makes this unfeasible. We present 2 cases where dose constraint was not achieved, and to a short follow-up of 20 months renal toxicity has not been documented. We recommend the lowest possible mean dose to the KT, but never compromising the CTV coverage, since morbimortality from recurrent or progressive cancer disease outweighs the risk of graft injury.
AIM: Describe characteristics and outcomes of three patients treated with pelvic radiation therapy after kidney transplant. BACKGROUND: The incidence of pelvic cancers in kidney transplant (KT) recipients is rising. Currently it is the leading cause of death. Moreover, treatment is challenging because anatomical variants, comorbidities, and associated treatments, which raises the concern of using radiotherapy (RT). RT has been discouraged due to the increased risk of urethral/ureteral stricture and KT dysfunction. MATERIALS AND METHODS: We reviewed the electronic health records and digital planning system of patients treated with pelvic RT between December 2013 and December 2018 to identify patients with previous KT. CASES DESCRIPTION: We describe three successful cases of KT patients in which modern techniques allowed full standard RT for pelvic malignances (2 prostate and 1 vaginal cancer) with or without elective pelvic nodal RT, without allograft toxicity at short and long follow-up (up to 60 months). CONCLUSION: When needed, RT modern techniques remain a valid option with excellent oncologic results and acceptable toxicity. Physicians should give special considerations to accomplish all OAR dose constraints in the patient's specific setting. Recent publications recommend KT mean dose <4 Gy, but graft proximity to CTV makes this unfeasible. We present 2 cases where dose constraint was not achieved, and to a short follow-up of 20 months renal toxicity has not been documented. We recommend the lowest possible mean dose to the KT, but never compromising the CTV coverage, since morbimortality from recurrent or progressive cancer disease outweighs the risk of graft injury.
Authors: M Raschid Hoda; Amir Hamza; Francesco Greco; Sigrid Wagner; Olaf Reichelt; Hans Heynemann; Kersten Fischer; Paolo Fornara Journal: Nephrol Dial Transplant Date: 2010-04-12 Impact factor: 5.992
Authors: B Emami; J Lyman; A Brown; L Coia; M Goitein; J E Munzenrider; B Shank; L J Solin; M Wesson Journal: Int J Radiat Oncol Biol Phys Date: 1991-05-15 Impact factor: 7.038
Authors: M Gojdic; Z Zilinska; I Krajcovicova; P Lukacko; J Grezdo; B Obsitnik; J Breza; B Trebaticky Journal: Neoplasma Date: 2018-09-04 Impact factor: 2.575
Authors: Nicola Rosenfelder; Richard Corbett; Michelle Long; Carole Meehan; Neill Duncan; Vincent Khoo; Nicholas Van As Journal: Pract Radiat Oncol Date: 2014-09-26
Authors: Benjamin A Sherer; Krishnan Warrior; Karl Godlewski; Martin Hertl; Oyedolamu Olaitan; Ajay Nehra; Leslie Allan Deane Journal: Int Braz J Urol Date: 2017 Nov-Dec Impact factor: 1.541